Recommendations for antiretroviral therapy in HIV-infected children. Consensus statement of the German AIDS Pediatric Association (PAAD) and the German Society for Pediatric Infectiology (DGPI);Empfehlungen zur antiretroviralen therapie bei HIV-infizierten kindern: Konsensus-statement der pädiatrischen arbeitsgemeinschaft AIDS (PAAD) und der Deutschen Gesellschaft für Pädiatrische Infektiologie (DGPI)

Monatsschrift fur Kinderheilkunde

Volumn 154, Issue 6, 2006, Pages 565-577

  Niehues, Tim ^a   Baumann, Ulrich ^a   Buchholz, Bernd ^a   Dunsch, Dominik ^b   Funk, Markus ^b   Königs, Christoph ^b   Edelhäuser, Martin ^c   Neubert, Jennifer ^a   Notheis, Gundula ^d   Wintergerst, Uwe ^d  

^a Universitätskinderklinik Düsseldorf ^*  (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

AGITATION; AMNESIA; ANEMIA; ANOREXIA; BLOOD TOXICITY; CHILD; CHILDHOOD DISEASE; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DRUG INDICATION; DYSLIPIDEMIA; ESOPHAGUS ULCER; EUPHORIA; FEVER; FLATULENCE; GASTROINTESTINAL TOXICITY; GERMANY; HALLUCINATION; HEMOLYSIS; HEMOPHILIA; HEPATITIS; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; HYPERURICEMIA; HYPOPHOSPHATEMIA; INJECTION SITE REACTION; JAUNDICE; LACTIC ACIDOSIS; LIVER TOXICITY; MEDICAL SOCIETY; MYOPATHY; MYOSITIS; NEPHROLITHIASIS; NEUTROPENIA; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY DISORDER; RASH; RETINA PIGMENT DEGENERATION; REVIEW; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA;

EID: 33745621043     PISSN: 00269298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00112-006-1358-8     Document Type: Review

References (23)

1. Wiznia A, Stanley K, Krogstad P et al. (2000) Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial - PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. AIDS Res Hum Retroviruses 16: 1113-1121
2. de Martino M, Tovo PA, Balducci M et al. (2000) Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 284: 190-197
3. Chantry CJ, Byrd RS, Englund JA et al. (2003) Pediatric AIDS Clinical Trials Group Protocol 152 Study Team. Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. Pediatr Infect Dis J 22: 1033-1039
4. Paediatric European Network for Treatment of AIDS (PENTA) (2002) Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 359: 733-740
5. de Martino M, Tovo PA, Balducci M et al. (2000) Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 284: 190-197
6. Engelhorn C, Hoffmann F, Kurowski M et al. (2004) Longterm pharmacokinetics (PK) of Amprenavir (APV) in combination with delavirdine (DLV) in HIV-infected children. AIDS 18: 1473-1475
7. Sharland M, Blanche S, Castelli G et al. (2004) PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 5 [Suppl 2]: 61-86
8. Johnson M, DeJesus E, Rodriguez C et al. (2005) The influence of baseline protease inhibitor mutations on the efficacy of Ritonavir-boosted Atazanavir, Atazanavir plus Saquinavir, and Lopinavir/Ritonavir in patients who have experienced virologic failure on multiple HAART regimens. 12. Conference on Retroviruses and Opportunistic Infections, 22.-25.2.2005 in Boston, USA, Abstrakt 711
9. Lawrence J, Mayers DL, Hullsiek KH et al. (2003) Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 349: 837-846
10. Schieferstein C, Buhk T, Management von Nebenwirkungen. http://www.hiv.net/2010/buch/nw.htm
11. Farley J, Gona P, Crain M et al. (2005) Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C. J Acquir Immune Defic Syndr 38: 480-487
12. Jaquet D, Levine M, Ortega-Rodriguez E et al. (2000) Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 14: 2123-2128
13. Cheseaux JJ, Jotterand V, Aebi C et al. (2002) Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Defic Syndr 30: 288-293
14. Bergersen BM, Sandvik L, Bruun JN, Tonstad S (2004) Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 23: 625-630
15. McComsey G, Bhumbra N, Ma JF et al. (2003) Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics 111: e275-e281
16. Fisac C, Fumero E, Crespo M et al. (2005) Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 19: 917-925
17. European Paediatric Lipodystrophy Group (2004) Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 18: 1443-1451
18. Carr A, Miller J, Law M, Cooper DA (2000) A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14: F25-F32
19. Chene G, Angelini E, Cotte L et al. (2002) Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 34: 649-657
20. Church JA, Mitchell WG, Gonzalez-Gomez I et al. (2001) Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. J Pediatr 138: 748-751
21. Vigano A, Mora S (2004) Adverse effects of anti-retroviral therapy: focus on bone density. Expert Opin Drug Saf 3: 199-208
22. Paterson DL, Swindells S, Mohr J et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133: 21-30
23. Van Dyke RB, Lee S, Johnson GM et al., Pediatric AIDS Clinical Trials Group Adherence Subcommittee Pediatric AIDS Clinical Trials Group 377 Study Team (2002) Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human mmunodeficiency virus infection. Pediatrics 109: e61